Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 2, 2012

View Archived Issues

Lorvotuzumab mertansine evaluated in patients with solid tumors

Merck KGaA discloses novel agents for cancer

GlaxoSmithKline patents new RIP-2 inhibitors

Daiichi Sankyo divulges new Mdm2/p53 inhibitors

Novel AMPK activators synthesized at GlaxoSmithKline

Japanese researchers disclose new glucokinase activators

Plavix gets Japanese approval for additional indication

Intramuscular injection formulation of Zyprexa approved in Japan

Biotie Therapies describes novel SSAO inhibitors

Suini approved in Japan for type 2 diabetes

Bayer HealthCare joins forces with Evotec on endometriosis

Shionogi and Kotobuki Pharmaceutical sign license agreement for cholesterol absorption inhibitor

Ramucirumab shows activity in non-small cell lung cancer

Progenics Pharmaceuticals begins phase II PSMA-ADC trial in prostate cancer

Dacogen gains approval in the E.U. for acute myeloid leukemia

Results of lenvatinib trials in different kinds of cancer presented

Humira obtains new approval in the U.S.

Novo Nordisk discontinues development of vatreptacog alfa

Subcutaneous Velcade approved in Europe for multiple myeloma

Novo Nordisk's insulin degludec obtains first approval

Antisense Therapeutics provides update on ATL-1102 collaboration

Medicure to develop transdermal formulation of Aggrastat

Apricus Biosciences plans Canadian submission for MycoVa

FDA approval sought for tivozanib

A.P. Pharma resubmits APF-530 NDA

European approval for Seebri Breezhaler

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...